Back4DMedical Limited Overview

4DMedical Limited EBIT

Latest ebit for 4DX.AX: $-100M, below the sector sector average of $2.6T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$30.90M
↓ 28.75% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$104.90M
↓ 56.45% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

4DMedical Limited (4DX.AX) FAQ

The latest EBIT for 4DX.AX is $-100M as of June 2026. That compares with $-67M in the prior-year period — down 56.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside 4DMedical Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4DX.AX's EBIT moved from $-67M to $-100M — a 56.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 4DMedical Limited's operating scale or balance-sheet position.

Against its sector companies, 4DX.AX currently prints $-100M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at 4DMedical Limited's growth, margins, and balance sheet.

A EBIT figure of $-100M for 4DX.AX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 4DX.AX's EBIT ($-100M), review year-over-year change from $-67M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.